Navigation Links
Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
Date:9/10/2009

cleCare.com.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. The personalized oncology services division assists physicians by maximizing personalized treatment options for their cancer patients through access to expert medical information panels and development of personalized Tumorgrafts from their patient's fresh tumor.

www.championsbiotechnology.com

www.personalizedcancertreatment.com

This press release contains "forward-looking statements
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
2. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
3. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
4. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
5. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
6. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
8. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
9. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
10. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
11. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...e-FirstCall/ -- BlueFire Ethanol Fuels, Inc. (OTC ...ng the world,s transportation fuel paradigm throug...ic wastes, has been ranked number 19 on the Biofu...ioenergy;" the company,s second consecutive year i...Ethanol among the top 20 bioenergy companies for t...
(Date:12/3/2009).../ -- Nikon Corporation, an innovator of advanced o...gned a licensing agreement with Harvard University...ptical Reconstruction Microscopy (STORM) technolog...nufacture STORM enabled microscopy systems and mar...ration President, Mr. Michio Kariya, and Nikon Ins...
(Date:12/3/2009)...FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: ...elopment of compounds for the treatment of cardiov...t it has completed the last patient visit in its P...The FDG-PET trial enrolled 52 patients and was car...ing Massachusetts General Hospital, Mount Sinai Sc...
(Date:12/3/2009)...ire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ...ase its financial results for the second quarter o...m. EST and will host a conference call and webcast...ame day. ,, Peregrine,s senior management will ...nded October 31, 2009 and will review recent opera...
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
...y unveils landmark program to help clients avoid c...n collecting outcomes data, LINCOLN, R.I., July 1... questioning the integrity of outcomes data in cli...rsy has been in the news. The,truth is, no matter ...d,for, mistakes are easy to make and difficult to ...
...TON, N.J., July 15 Pharmasset, Inc.,(Nasdaq: VRU...itive,agreements dated July 14, 2008 with a select...0 shares of its common stock in a "registered,dire...e the shares at a,purchase price of $17.85 per sha...5.9 million to Pharmasset, before deducting placem...
...A, July 15 CryoLife, Inc. (NYSE: CRY ),a biomate...y, announced,today that second quarter 2008 financ... 2008. The Company will hold a teleconference call... 31, 2008, to discuss the,results, followed by a q...erson, president and CEO of CryoLife, Inc., To li...
Other Biology Technology:QualityMetric Announces QM Certified Scoring Program 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 3CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:12/4/2009)...matical model of heart cells, University of Iowa i...al enzyme, calmodulin kinase II (CaM kinase), disr... The study, which also involved Columbia Universit...S Computational Biology . , "Recently, research...nase II as a critical regulator of the heart,s res...
(Date:12/3/2009)... N.J., Dec. 3 BIO-key In...ader in wireless public safety and finger-based bi... majority of its shareholders at a Special Shareho...ompany,s Law Enforcement Division to Interact911 M... cast in favor and 1.2% were opposed. ,, (Logo:...
(Date:12/3/2009)...learn new information and adapt to changes in our ...emories, appears to lie in the minute junctions wh...udy by NYU Langone Medicine Center researchers. Th...al Nature . , The scientists, led by Wen-Biao ...uroscience at NYU School of Medicine, discovered t...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Lifelong memories linked to stable nerve connections 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 1AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 3AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 4NIA Says Health Care Will Cause U S Dollar Collapse 50998 1NIA Says Health Care Will Cause U S Dollar Collapse 50998 2NIA Says Health Care Will Cause U S Dollar Collapse 50998 3Spa Chefs Prepare You for a Healthy Summer 50996 1Spa Chefs Prepare You for a Healthy Summer 50996 2
...niversity Medical Center scientists have developed...ents with early-stage lung cancer will need chemot...xic regimen of drugs. , The test has the potenti...nding chemotherapy for patients who are currently ...Duke,s Institute for Genome Sciences & Policy....
...wing gentle puffs of air onto a mouse,s whiskers a...iscovering that a long-overlooked signaling system... , The work is the latest in a growing body of evi...ytes aren,t simply support cells but are stars of ...he University of Rochester Medical Center who did ...
...ein long thought to provide only mechanical suppor...ling apart turns out to have much wider utility. I...d to also influence wound healing and maintain the... to Johns Hopkins researchers. , The wound-healing...eds light on how the body repairs wounds and may h...
Other Biology News:First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Flick of whiskers helps tease out brain's 'shadow' signaling system 2Flick of whiskers helps tease out brain's 'shadow' signaling system 3Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 2Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 3
Nick Translation System from Invitrogen
...ble, easy-to-use and makes identifying your sample...asy to use Labels withstand extreme lab conditio...te stamp Laboratory symbols Affordable-every t...re efficient Banner mode for general labeling ...
cAMP[125I] Direct SPA Screening Biotrak Assay from GE Healthcare, formerly Amersham Biosciences
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: